Vaccine has been approved in China, Mexico, Pakistan, Hungary and Chile
Provides timely clinical protection for adults aged 18 and above, including those over 60
TIANJIN, China, May 24, 2021 /PRNewswire/ CanSino Biologics Inc. ( CanSinoBIO ) (SHSE: 688185, HKEX: 06185) today announced that its Recombinant Novel Coronavirus Vaccine, (Adenovirus Type 5 Vector) ( Ad5-nCoV , trade name: Convidecia™), has been granted a Good Manufacturing Practice ( GMP ) certificate by the Hungarian National Institute of Pharmacy and Nutrition (OGYÉI). The certification was issued on May 21, 2021 after a thorough inspection of CanSinoBIO s production of Convidecia™.
The GMP certificate recognizes that CanSinoBIO s manufacturing facilities and quality control system comply with the high production standards and guidelines required by the European Union ( EU ). The EU GMP certification is required to import COVID-19 vaccines into the European Union and is regarded as a recognition of leading ind
Share this article
Share this article
Continues to boost production capacity to meet increasing demand
Safe, stable storage and transportation between 2°C and 8°C, accessible by under-developed regions
95.47% effective overall in preventing severe COVID-19 diseases 14 days after vaccination
Vaccines provide timely mass protection for adults aged 18 and above, including those over 60
TIANJIN, China, March 22, 2021 /PRNewswire/ CanSinoBIO Biologics Inc. ( CanSinoBIO ) (HKEX: 06185) today announced that the Hungarian National Institute of Pharmacy and Nutrition (OGYÉI) granted emergency use authorization for its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) ( Ad5-nCoV , trade name: Convidecia™). The approval is based on the vaccine s interim results for Phase III clinical trial and marks the first approval of Convidecia™ in an European Union member state.
CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine Convidecia in Chile finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Safe, stable storage and transportation between 2°C and 8°C, accessible by under-developed regions
95.47% effective overall in preventing severe COVID-19 diseases 14 days after vaccination
TIANJIN, China, April 8, 2021 /PRNewswire/ CanSino Biologics Inc. ( CanSinoBIO ) (HKEX: 06185) today announced that the Instituto de Salud Pública de Chile ( ISP ) granted emergency use authorization for its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) ( Ad5-nCoV , trade name: Convidecia™). This marks the first approval of Convidecia™ in South America and the first single-dose COVID-19 vaccine approved for emergency use in Chile.
On February 25, 2021, Convidecia™ was granted a conditional marketing authorization by the National Medical Products Administration of China ( NMPA ), the first of its kind authorized in China. Globally, Convidecia™ received authorization for emergency use by the Hungarian National Institute of Pharmacy and Nutrition (OGYÉI) in Ma
CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine Convidecia™ in Chile prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.